Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI-0401 in Acute Cellular Renal Allograft Rejection
NCT00805909Phase 2Completed
- Sponsor
- Lightchain Bioscience
- Start
- Aug 2007
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of foralumab in acute cellular renal allograft rejection (TCMR), sponsored by Lightchain Bioscience. Started Aug 2007; status: completed.
02
Drugs
foralumab
03
Conditions
acute cellular renal allograft rejection (TCMR)
Beyond the preview
Go deeper on NCT00805909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805909.